Entities / Company
Qiagen.
company
- Reports this week
- 0
- Active events
- 0
- Connections
- 85
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Thierry Bernard became the CEO of Qiagen on August 8, 2026.Some support2 reports
-
Qiagen operates within the District of Delaware.Some support1 report
-
Qiagen received FDA clearance for its diagnostic product, QIAstat-Dx Rise, expanding access in the U.S. on September 3, 2025.Well supported3 reports
-
Qiagen reported sales declines in EMEA and overall sales in the low teens year over year in August 2026.Some support1 report
-
Berenberg Bank has set a target price for Qiagen shares.Some support4 reports
Gone quiet
No new reports in 90+ days-
Illumina, AbbVie, Abbott Laboratories, Qiagen, and Eli Lilly are major players in the US personalized medicine market and are investing in related R&D.Some support1 report1 development inside
-
A market report published from Dublin details advanced molecular diagnostics and key players in the hemato-oncology testing market.Some support1 report
-
The IVD market in India is driven by NCDs, with key companies like Roche, Sysmex, Danaher, Qiagen, and Quidel leading innovation-driven growth.Some support1 report
-
Golden Cross (Q10290401) and Qiagen (Q315287) experienced a Golden Cross on June 23, 2025, when the 50-day moving average crossed above the 200-day moving average.Speculative1 report
-
Qiagen has shown better earnings estimate revision trends.Speculative1 report
-
Collaboration between Qiagen and Incyte to develop a novel diagnostic panel, leveraging FDA approvals for market access in the US.Speculative2 reports
-
Qiagen, Gencurix, and Genoox collaborated on July 3, 2025, to provide oncology assays and improve genetic data analysis capacity.Speculative1 report
-
Exact Sciences and Qiagen are considered value stocks in the sector as of July 10, 2025.Some support1 report
-
Illumina and Qiagen are noted as top players in the tumor profiling market experiencing growth in Europe.Some support1 report
-
Qiagen N.V. is a Netherlands-based holding company.Some support12 reports1 development inside
-
Qiagen and CervoMed Inc. are both companies operating within the medical/biomedical sector.Some support1 report
-
GE HealthCare, Exagen Inc., Biogen, and Qiagen were identified as key market players in the Personalized Medicine Market.Some support1 report
-
Qiagen and Incyte formed a partnership to develop a companion diagnostic for mutant calreticulin.Some support1 report
-
Qiagen, a Netherlands-based company, announced a share offering with restrictions on persons in South Africa.Some support1 report
-
Qiagen is facing an investigation into investor claims, handled by the law firm Pomerantz LLP.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Qiagen this week
News at the entities that move Qiagen most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Qiagen
-
Berenberg Bank TransactionalBerenberg Bank restated a buy rating on RWS.Moves Qiagen
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Qiagen
-
China Shared contextThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Qiagen
-
Frankfurt StructuralHarold Toliver held academic positions at Johns Hopkins University and showcased his work at the Frankfurt Book Fair.Moves Qiagen
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Qiagen
Connections
The 18 strongest of 85, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Incyte Operational
Qiagen and Incyte maintain a strategic partnership focused on developing and supplying companion diagnostics for Incyte's targeted therapies.
-
Thierry Bernard Structural
Thierry Bernard serves as the CEO of Qiagen.
-
Securities and Exchange Commission Structural
Qiagen is subject to formal regulatory reporting requirements mandated by the SEC.
-
Bank of America Structural
Bank of America holds a significant financial stake in Qiagen.
-
FDA Structural
FDA provides necessary regulatory clearance and market listing for Qiagen's products to operate in the U.S. market.
-
Frankfurt Structural
Qiagen is formally listed and trades on the Frankfurt Stock Exchange.
-
Morgan Stanley Operational
Morgan Stanley provides analyst rating updates to Qiagen.
-
China Shared context
Qiagen operates within the market context of China, where geopolitical factors like import tariffs impact its business profitability and sales performance.
Show all 18 connections
-
Berenberg Bank Transactional
Berenberg Bank provides financial analysis, including target prices and ratings, for Qiagen shares.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides financial ratings and price targets for Qiagen.
-
TD Cowen Mentioned together
TD Cowen issues ratings on Qiagen shares.
-
Banque cantonale vaudoise Transactional
Banque cantonale vaudoise increased its stake in Qiagen's stock.
-
Thermo Fisher Scientific Inc. Mentioned together
The companies are frequently co-mentioned in financial reports and comparisons.
-
Delaware Shared context
Qiagen operates within the District of Delaware.
-
AllianceBernstein Transactional
AllianceBernstein is listed as an interested party in a potential acquisition involving Qiagen.
-
EQT Transactional
EQT is mentioned as a potential interested party in acquisitions within the companies' shared market.
-
Netherlands Shared context
Qiagen is headquartered and operates within the Netherlands.
-
Europe Shared context
Qiagen operates within the European market context, which is subject to regional sales performance fluctuations.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
4 eventsJune 2026
16 events- Qiagen received FDA clearance for its diagnostic product, QIAstat-Dx Rise, expanding access in the U.S. on September 3, 2025.
- Illumina, AbbVie, Abbott Laboratories, Qiagen, and Eli Lilly are major players in the US personalized medicine market and are investing in related R&D.
- A market report published from Dublin details advanced molecular diagnostics and key players in the hemato-oncology testing market.
- The IVD market in India is driven by NCDs, with key companies like Roche, Sysmex, Danaher, Qiagen, and Quidel leading innovation-driven growth.
- Golden Cross (Q10290401) and Qiagen (Q315287) experienced a Golden Cross on June 23, 2025, when the 50-day moving average crossed above the 200-day moving average.
- Qiagen has shown better earnings estimate revision trends.
- Collaboration between Qiagen and Incyte to develop a novel diagnostic panel, leveraging FDA approvals for market access in the US.
- Qiagen, Gencurix, and Genoox collaborated on July 3, 2025, to provide oncology assays and improve genetic data analysis capacity.
- Exact Sciences and Qiagen are considered value stocks in the sector as of July 10, 2025.
- Illumina and Qiagen are noted as top players in the tumor profiling market experiencing growth in Europe.
- Qiagen N.V. is a Netherlands-based holding company.
- Qiagen and CervoMed Inc. are both companies operating within the medical/biomedical sector.
- GE HealthCare, Exagen Inc., Biogen, and Qiagen were identified as key market players in the Personalized Medicine Market.
- Qiagen and Incyte formed a partnership to develop a companion diagnostic for mutant calreticulin.
- Qiagen, a Netherlands-based company, announced a share offering with restrictions on persons in South Africa.
- Qiagen is facing an investigation into investor claims, handled by the law firm Pomerantz LLP.